Company Update (NYSE:BMY): Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival in Advanced Renal Cell Carcinoma vs. a Standard of Care, in Patients Who Have Received Prior Anti-Angiogenic Thera

[Business Wire] – Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo injection, for intravenous use, for the tre Read more on this. Bristol-Myers Squibb Company . . . → Read More: Company Update (NYSE:BMY): Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival in Advanced Renal Cell Carcinoma vs. a Standard of Care, in Patients Who Have Received Prior Anti-Angiogenic Thera Similar Articles: Company Update (NYSE:BMY): U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Advanced Renal Cell Carcinoma Stock Update (NYSE:BMY): Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer